CXCL16 and pancreatic ductal adenocarcinoma: Expression of CXCR6 and CXCL16, comprising another significant chemokine axis, is evaluated in several cancers, such as renal [33], rectal [34], pancreatic ductal adenocarcinoma [35], nasopharyngeal carcinoma, and melanoma [36].